It's a game changer for the FDA to officially recognize the causative role chronic inflammation plays in the development of CHD. But there are many on this board who now have heightened concerns because we (Amarin) are still SELLING Triglyceride pills! Some believe we should stay the course and not rock the FDA boat, just keep selling and wait for Reduce-It. It looks to me that if Amarin doesn't get the real Vascepa message out there soon, then our competition will do it for us! AZN, GSK, MRK...they'll have no qualms over sinking FDAs boat and they won't be sitting around "waiting for Reduce-It"! They'll get their own products to market that "reduce inflammation" and in the process they'll either bury Vascepa or steal it from the corpse of Amarin. Right now, Amarin should be doing what's best for Amarin (and us), and that means anything it takes to stay alive! Sadly though, this company acts like it has a death wish. Not much else to say.....RIP.
News 
Market Data 
Discover 
